Please assess the completion status of the following clinical trial:

Trial Title: Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent provided.~* 18 years old or older.~* Histologically- or cytologically- confirmed diagnosis of solid tumor malignancy or lymphoma that is not responsive to accepted standard therapies or for which there is no standard or curative therapy.~* Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale.~* A life expectancy of \> 12 weeks.~* Able to swallow and retain oral medication.~* A male is eligible to enter and participate in the study if he either:~* agrees to abstain from sexual intercourse from the first dose of study drug and until 21 days after last dose of study medication, or~* agrees to use a condom and occlusive cap (diaphragm or cervical/vault cap) with spermicidal foam/gel/film/cream/suppository from the first dose of study drug and until 21 days after last dose of study medication, or~* is surgically sterile. NOTE: Male patients must use contraception to prevent pregnancy in a female partner and prevent exposure of any partner to semen by any means (refer to protocol).~* A female is eligible to enroll in the study if she is of:~Non-child bearing potential (i.e., physiologically incapable of becoming pregnant) including any woman who is characterized by at least one of the following:~* Has had a hysterectomy~* Has had a bilateral oophorectomy (ovariectomy)~* Has had a bilateral tubal ligation~* Is post-menopausal (total cessation of menses for ≥ 1 year) Childbearing potential, has a negative serum pregnancy test at screening, and agrees to one of the following from at least 2 weeks prior to the first dose of study drug and until 21 days after last dose of study medication:~* Use an intrauterine device (IUD) with a documented failure rate of~* less than 1% per year.~* Have intercourse only with a vasectomized partner who is sterile~* and is the sole sexual partner for that woman.~* Complete abstinence from sexual intercourse.~* Use double barrier contraception defined as condom with~* spermicidal jelly, foam, suppository, or film; OR diaphragm with~* spermicide; OR male condom and diaphragm. NOTE: Oral contraceptives are not reliable due to potential for drug-drug interaction.~* Adequate organ system function as defined in the protocol.~Exclusion Criteria:~* Use of an investigational anti-cancer drug within 28 days or 5 half-lives preceding the first dose of GSK1059615.~* Chemotherapy within the last 3 weeks (6 weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity are permitted with approval of the GSK medical monitor if administered at least 2 weeks prior to the first dose of study drug.~* Trastuzumab within the last 4 weeks.~* Any major surgery, radiotherapy, or immunotherapy within the last 4 weeks.~* Prior use of any PI3K inhibitor.~* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug. (To date there are no known FDA approved drugs chemically related to GSK1059615).~* Current use of a prohibited medication or requires any of these medications during treatment with GSK1059615 as per protocol.~* Current use of warfarin for therapeutic anticoagulation.~* NOTE: Low molecular weight heparin and prophylactic low-dose warfarin are permitted. PT/PTT must meet the inclusion criteria. Patients taking warfarin must have their INR followed closely.~* Presence of an active gastrointestinal disease or other condition known to interfere significantly with the absorption, distribution, metabolism, or excretion of drugs.~* Unresolved toxicity greater than Grade 1 from previous anti-cancer therapy except alopecia. Patients with stable Grade 2 neuropathy can be enrolled with approval by the GSK Medical Monitor.~* QTc interval ≥ 480 msecs.~* History of acute coronary syndromes (including unstable angina and myocardial infarction), atrial fibrillation, coronary angioplasty, or stenting within the past 24 weeks.~* Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.~* Symptomatic or untreated leptomeningeal or brain metastases. Patients previously treated for these conditions who are asymptomatic and off of corticosteroid and P450-inducing anti-epileptic medication for at least 2 months are permitted.~* Primary malignancy of the central nervous system.~* Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.~* Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol.~* Nursing female.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohorts (Type: EXPERIMENTAL): The starting dose is 6mg once daily (QD); dose is to be escalated using a standard 3 + 3 dose escalation scheme.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy